The DOI matches its Crossref record.
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
Abstract
BACKGROUND AND OBJECTIVE: Recent in vitro studies have suggested an important role of cytochrome P450 (CYP) 2B6 and CYP2C19 in methadone metabolism. We aimed to determine the influence of CYP2B6, CYP2C9, and CYP2C19 genetic polymorphism on methadone pharmacokinetics and on the response to treatment. METHODS: We included 209 patients in methadone maintenance treatment on the basis of their response to treatment and their daily methadone dose. Patients were genotyped for CYP2B6, CYP2C9, and CYP2C19. Steady-state trough and peak (R)-, (S)-, and (R,S)-plasma levels and peak-to-trough plasma level ratios were measured. RESULTS: CYP2B6 genotype influences (S)-methadone and, to a lesser extent, (R)-methadone plasma levels, with the median trough (S)-methadone plasma levels being 105, 122, and 209 ng . kg/mL . mg for the noncarriers of allele *6, heterozygous carriers, and homozygous carriers (*6/*6), respectively (P = .0004). CYP2C9 and CYP2C19 genotypes do not influence methadone plasma levels. Lower peak and trough plasma levels of methadone and higher peak-to-trough ratios were measured in patients considered as nonresponders [median (R,S)-methadone trough plasma levels of 183 and 249 ng . kg/mL . mg (P = .0004) and median peak-to-trough ratios of 1.82 and 1.58 for high-dose nonresponders and high-dose responders, respectively (P = .0003)]. CONCLUSION: Although CYP2B6 influences (S)-methadone plasma levels, given that only (R)-methadone contributes to the opioid effect of this drug, a major influence of CYP2B6 genotype on response to treatment is unlikely and has not been shown in this study. Lower plasma levels of methadone in nonresponders, suggesting a higher clearance, and higher peak-to-trough ratios, suggesting a shorter elimination half-life, are in agreement with the usual clinical measures taken for such patients, which are to increase methadone dosages and to split the daily dose into several intakes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“In *6/*6 carriers (S)-methadone plasma levels were increased leading to potentially higher risk of severe cardiac arrhythmias and methadone associated deaths (Crettol et al., 2005; Eap et al., 2007; Bunten et al., 2011).”
BackgroundConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Self-citationAGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., Fric, M., Gerlach, M., Greiner, C., Gründer, G., et al. (2011) · Pharmacopsychiatry · doi:10.1055/s-0031-1286287 · Cited by 868
Self-citationPolymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Chiral Toxicology: It's the Same Thing…Only Different
Smith, S. W. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp097 · Cited by 602
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 490
Zanger, U. M., & Klein, K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00024 · Cited by 345
Somogyi, A. A., Barratt, D. T., & Coller, J. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100095 · Cited by 324
Polymorphic CYP2B6: Molecular Mechanisms and Emerging Clinical Significance
Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., H Hofmann, M., & Schwab, M. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.7.743 · Cited by 258
Eap, C. B., Crettol, S., Rougier, J.-S., Schläpfer, J., Sintra Grilo, L., Déglon, J.-J., Besson, J., Croquette-Krokar, M., Carrupt, P.-A., & Abriel, H. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100120 · Cited by 255
Self-citationQT Interval Screening in Methadone Maintenance Treatment: Report of a SAMHSA Expert Panel
Martin, J. A., Campbell, A., Killip, T., Kotz, M., Krantz, M. J., Kreek, M. J., McCarroll, B. A., Mehta, D., Payte, J. T., Stimmel, B., et al. (2011) · Journal of Addictive Diseases · doi:10.1080/10550887.2011.610710 · Cited by 87
“48 – 50 Stereoselectivity of CYP2B6 toward S -methadone has been demonstrated in vitro 51 and in vivo.”
Metadata
- Authors
- CRETTOL, S., DEGLON, J., BESSON, J., CROQUETTEKROKKAR, M., GOTHUEY, I., HAMMIG, R., MONNAT, M., HUTTEMANN, H., BAUMANN, P., & EAP, C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-12
- Volume
- 78
- Issue
- 6
- Pages
- 593-604
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2032191165
- Cited by
- 228
- References
- 0
- FWCI
- 11.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.